Thank you for sharing!

Your article was successfully shared with the contacts you provided.

SAN FRANCISCO-Pfizer this week officially killed plans to open a biotech research center in leased space near UCSF’s Mission Bay Campus. The New York-based drug company says it is in discussions with the building owner Alexandria Real Estate Equities to get out of the long-term, 105,000-square-foot lease it signed this time last year.

Pfizer’s Biotherapeutics and Bioinnovation Center was scheduled to occupy the upper west-wing floors of 455 Mission Bay in early 2010, which is when it is scheduled for completion. The company reportedly held an option to lease an additional 50,000 sf in the east wing.

Instead, Pfizer’s existing biotheraputics research operation will remain in South San Francisco at 259 East Grand Avenue, the home of Rinat Neuroscience, a company it acquired in 2006, and the man slated to head the new center, Bay Area biotech entrepreneur Corey Goodman, is no longer with the company.

In January, Pfizer bid $68 million for Wyeth Pharmaceuticals, a Madison, NJ-based drugmaker with a large biotech research group. The acquisition is expected to close later this year. In April, it was announced that Wyeth executive Mikael Dolsten would head biotech research at the combined companies, but said it still planned to occupy its new space at Mission Bay.

Pfizer spokeswoman Joan Campion tells GlobeSt.com that ultimately the acquisition of Wyeth—and the global real estate portfolio that comes with it–did indeed play into the company’s decision not to relocate the local operation to Mission Bay. Also taken into account were overall occupancy costs and the disruption to science caused by the relocation of a research operation.

“It was a real estate decision,” Campion said after declining to discuss the cost to terminate the Mission Bay lease. “Economics was a factor but not the only factor.”

Want to continue reading?
Become a Free ALM Digital Reader.

Once you are an ALM digital member, you’ll receive:

  • Unlimited access to GlobeSt and other free ALM publications
  • Access to 15 years of GlobeSt archives
  • Your choice of GlobeSt digital newsletters and over 70 others from popular sister publications
  • 1 free article* every 30 days across the ALM subscription network
  • Exclusive discounts on ALM events and publications

*May exclude premium content
Already have an account?


Join GlobeSt

Don't miss crucial news and insights you need to make informed commercial real estate decisions. Join GlobeSt.com now!

  • Free unlimited access to GlobeSt.com's trusted and independent team of experts who provide commercial real estate owners, investors, developers, brokers and finance professionals with comprehensive coverage, analysis and best practices necessary to innovate and build business.
  • Exclusive discounts on ALM and GlobeSt events.
  • Access to other award-winning ALM websites including ThinkAdvisor.com and Law.com.

Already have an account? Sign In Now
Join GlobeSt

Copyright © 2021 ALM Media Properties, LLC. All Rights Reserved.